Naidoo, DeveshWu, AnnBrilliant, Murray HDenny, JoshuaIngram, ChristieKitchner, Terrie ELinneman, James GMcGeachie, MichaelRoden, Dan MShaffer, Christian MShah, AnushiWeeke, PeterWeiss, ScottXu, HuaMedina, Marisa W2016-01-042014Naidoo, D., A. C. Wu, M. H. Brilliant, J. Denny, C. Ingram, T. E. Kitchner, J. G. Linneman, et al. 2014. “A polymorphism in HLA-G modifies statin benefit in asthma.” The pharmacogenomics journal 15 (3): 272-277. doi:10.1038/tpj.2014.55. http://dx.doi.org/10.1038/tpj.2014.55.1470-269Xhttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23993700Several reports have shown that statin treatment benefits patients with asthma, however inconsistent effects have been observed. The mir-152 family (148a, 148b and 152) has been implicated in asthma. These microRNAs suppress HLA-G expression, and rs1063320, a common SNP in the HLA-G 3’UTR which is associated with asthma risk, modulates miRNA binding. We report that statins up-regulate mir-148b and 152, and affect HLA-G expression in an rs1063320 dependent fashion. In addition, we found that individuals who carried the G minor allele of rs1063320 had reduced asthma related exacerbations (emergency department visits, hospitalizations or oral steroid use) compared to non-carriers (p=0.03) in statin users ascertained in the Personalized Medicine Research Project at the Marshfield Clinic (n=421). These findings support the hypothesis that rs1063320 modifies the effect of statin benefit in asthma, and thus may contribute to variation in statin efficacy for the management of this disease.en-USpharmacogeneticsHLA-Gstatinasthmamir-148mir-152Journal Article2016-01-0410.1038/tpj.2014.55